• 1. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purinones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Purinones

Introduction to 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one (CAS No. 93079-86-8) in Modern Chemical and Pharmaceutical Research

The compound 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one, identified by the CAS number 93079-86-8, represents a significant advancement in the field of chemical and pharmaceutical research. This heterocyclic compound, characterized by its unique structural framework, has garnered considerable attention due to its potential applications in medicinal chemistry and drug development. The molecular structure of this compound incorporates a purine core, modified with specific functional groups that enhance its pharmacological properties.

One of the most striking features of 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one is its 6-(5-oxohexyl)oxy substituent. This group introduces a hydrophilic character to the molecule, making it more soluble in aqueous environments while maintaining sufficient lipophilicity for effective cellular penetration. Such a balance is crucial for designing compounds that can interact efficiently with biological targets. The presence of the 5-oxohexyl moiety also suggests potential interactions with enzymes and receptors involved in metabolic pathways, which is a key consideration in drug design.

Recent research has highlighted the compound's potential in addressing various therapeutic challenges. Studies have indicated that derivatives of this molecule may exhibit inhibitory effects on certain kinases and enzymes implicated in inflammation and cancer progression. The dimethyl groups at the 3-position of the purine ring contribute to the stability of the molecule, enhancing its shelf life and bioavailability. Furthermore, the 3,7-dihydro configuration suggests a rigid scaffold that can be further modified to improve binding affinity to target proteins.

In the realm of drug discovery, the synthesis of analogs based on 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one has been a focal point for medicinal chemists. By strategically modifying the 5-oxohexyl group or introducing additional functional moieties, researchers aim to fine-tune the pharmacokinetic and pharmacodynamic properties of these compounds. Preliminary computational studies have suggested that such modifications could lead to enhanced efficacy with reduced side effects.

The structural motif of this compound also finds relevance in the development of antiviral agents. The purine core is a well-known scaffold in nucleoside analogs, which have been successfully used to treat viral infections such as HIV and hepatitis B. The unique substitution pattern in 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one may confer resistance to viral polymerases while maintaining antiviral activity. This makes it an attractive candidate for further exploration in antiviral drug development pipelines.

Another area where this compound shows promise is in neuropharmacology. The ability of its structure to cross the blood-brain barrier is crucial for treating central nervous system disorders. The combination of hydrophilic and lipophilic regions ensures optimal solubility and membrane permeability. Current research is exploring its potential as a precursor for neuroprotective agents or as an adjunct therapy in neurodegenerative diseases.

The synthesis of 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one involves multi-step organic reactions that require precise control over reaction conditions to achieve high yields and purity. Advances in synthetic methodologies have enabled researchers to produce this compound more efficiently than ever before. Techniques such as catalytic hydrogenation and selective oxidation are commonly employed to construct the core purine ring and introduce the desired substituents.

Evaluation of 3,7-Dihydro-3,7-dimethyl-6-(5-oxohexyl)oxy-2H-purin-2-one in preclinical models has provided valuable insights into its biological activity. In vitro assays have demonstrated inhibitory effects on enzymes such as COX and lipoxygenase, which are involved in inflammatory responses. Additionally, cell-based assays have shown potential anti-proliferative effects on certain cancer cell lines. These findings underscore the compound's therapeutic potential and justify further investigation into its mechanisms of action.

The future direction of research on 3,7-Dihydro-3,7-dimethyl-6-(5-oxyhexyl)oxy - 2H-purin - 2-one (CAS No. 93079 - 86 - 8) is likely to involve structure-based drug design approaches. By leveraging high-resolution crystallography data and molecular dynamics simulations, researchers can gain detailed insights into how this compound interacts with biological targets at an atomic level. Such information is invaluable for optimizing its potency and selectivity.

In conclusion, 3 , 7 - Dihydro - 3 , 7 - dimethyl - 6 - ( 5 - oxohexyl ) oxy - 2 H - purin - 2 - one represents a promising candidate for further exploration in pharmaceutical research . Its unique structural features , combined with preliminary evidence of biological activity , make it an exciting prospect for developing new therapeutics . As our understanding of molecular interactions continues to evolve , compounds like this are poised to play a pivotal role in addressing some of today's most pressing medical challenges .

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)